Kahr medical
OverviewSuggest Edit
Kahr medical is a company that develops a novel drug platform designed to offer immuno-oncology therapies. Its platform uses the Dual Signaling Proteins (DSP) technology for the development of third-generation biological drugs having fusion-protein molecules for the treatment of multiple types of cancer, enabling doctors to manage the immune system and target complex biological processes within the immune system.
| Type | Private | |
| Founded | 2005 | |
| HQ | Jerusalem, IL | Map |
| Website | kahrbio.com |
Recent NewsAll News
- KAHR Medical presents at 21st Annual Needham Virtual Healthcare Conference
- KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers
- KAHR Announces FDA Clearance of IND Application for Phase 1b Trial of its Lead Anti-CD47 Candidate in Blood Cancers
- Effective Remote Care Through Home-Use Medical Devices
Latest Updates
| Employees (est.) (Apr 2022) | 29 | |
| Cybersecurity rating | A | More |
Key People/Management at Kahr medical
Yaron Pereg
CEO
Tomer Cohen
CFO
Ayelet Chajut
CTO
Adam Foley-Comer
CMO
Iris Pecker
VP CMC
Rinat Tabakman
VP Development
Kahr medical Financials and Metrics
Summary Metrics
Founding Date | 2005 |
Kahr medical total Funding | $40 m |
Kahr medical latest funding size | $18 m |
Time since last funding | 2 years ago |
Kahr medical investors | Korea Investment Partners, Sanofi Aventis, HBL Hadasit Bio Holdings, Mirae Asset Venture Investment, DSC Investment, Pavilion Capital, Flerie Invest, Oriella Ltd. |
Kahr medical's latest funding round in February 2020 was reported to be $18 m. In total, Kahr medical has raised $40 m
Kahr medical Cybersecurity Score
Kahr medical Online and Social Media Presence
13 Twitter followers
Kahr medical has 13 Twitter Followers. The number of followers has increased 15.8% quarter over quarter
Kahr medical's Trends
Kahr medical Blogs
May 02, 2022
KAHR Medical presents at 21st Annual Needham Virtual Healthcare Conference
KAHR, a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins, presented today at the 21st Annual Needham Virtual Healthcare Conference. A link to the webcast recording is available below. https://wsw.com/webcast/needham117/kahr/2236354
The post KAHR Medical pre…
February 27, 2022
KAHR and Cancer Focus Fund Announce First Patient Dosed in Phase 1b Clinical Trial of Anti-CD47 Product Candidate DSP107 in Blood Cancers
KAHR, a clinical stage oncology company developing novel dual-targeting fusion protein therapeutics, and Cancer Focus Fund, LP, a unique investment fund established in collaboration with The University of Texas MD Anderson Cancer Center to provide funding and clinical expertise to advance promising …
January 18, 2022
KAHR Announces FDA Clearance of IND Application for Phase 1b Trial of its Lead Anti-CD47 Candidate in Blood Cancers
KAHR, a cancer immunotherapy company developing novel multifunctional immuno-recruitment proteins, today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application for KAHR’s Phase 1b clinical trial of DSP107, a first-in-class CD47x41BB targ…
October 20, 2021
Effective Remote Care Through Home-Use Medical Devices
BlueWind Initiates U.S. Enrollment
in Pivotal Trial of the RENOVA iStim
and Expands Leadership Team
Adding Two MedTech Veterans
The post Effective Remote Care Through Home-Use Medical Devices appeared first on KAHR.
June 08, 2021
KAHR Receives Investment from Cancer Focus Fund to Support Phase 1/2 Study of KAHR’s Lead Anti-CD47 Candidate in Blood Cancers
JERUSALEM and HOUSTON, May 26, 2021 /PRNewswire/ — KAHR, a clinical-stage cancer immunotherapy company developing novel bi-functional fusion proteins, and Cancer Focus Fund, LP, a unique venture capital fund established in collaboration with The University of Texas MD Anderson Cancer Center (MD Ande…
Kahr medical Frequently Asked Questions
When was Kahr medical founded?
Kahr medical was founded in 2005.
Who are Kahr medical key executives?
Kahr medical's key executives are Yaron Pereg, Tomer Cohen and Ayelet Chajut.
How many employees does Kahr medical have?
Kahr medical has 29 employees.
Who are Kahr medical competitors?
Competitors of Kahr medical include Alchemab Therapeutics, Priothera and Tollys.
Where are Kahr medical offices?
Kahr medical has an office in Jerusalem.
How many offices does Kahr medical have?
Kahr medical has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies